Monocytes and Macrophages in Systemic Sclerosis: Profibrotic Functions and Emerging IRF8-Dependent Regulation

Systemic sclerosis (SSc) is a clinically distinct autoimmune connective tissue disease characterized by immune dysregulation, vasculopathy, and excessive fibrosis. Monocytes and macrophages (Mo/Mφ) contribute to these processes through heterogeneous tissue-dependent states that are not sufficiently represented by a binary M1/M2 framework. Human blood and tissue studies, including recent single-cell and spatial analyses, have repeatedly identified hybrid activated monocytes and monocyte-derived macrophages associated with skin or lung involvement. Classical studies have established several Mo/Mφ-linked profibrotic mechanisms in SSc, including the secretion of cytokines, chemokines, and growth factors; organization of macrophage–stromal signaling niches; production and remodeling of the extracellular matrix; monocyte plasticity toward vascular and mesenchymal lineages; and defective efferocytosis and resolution. Upstream of these effector outputs, transcriptional, epigenetic, and metabolic programs are increasingly recognized as key regulators. As one example relevant to Mo/Mφ differentiation, we have focused on interferon regulatory factor 8 (IRF8), showing reduced IRF8 expression in circulating monocytes from diffuse cutaneous SSc associated with skin fibrosis. Experimentally, IRF8 silencing and myeloid-specific Irf8 deletion promote profibrotic features; however, the functional direction of IRF8 across lineages and tissues remains incompletely defined. Several established and emerging SSc therapeutic strategies are thought to act at least in part on the Mo/Mφ compartment, although direct SSc-derived cellular evidence remains limited. This review synthesizes Mo/Mφ diversity and effector functions in SSc and outlines therapeutic implications, highlighting the need for lineage- and tissue-resolved profiling of Mo/Mφ and mechanistic dissection of their upstream programs as a foundation for rational therapeutic strategies in SSc.

Authors

Institutions

Publication Details

Journal
Sclerosis
Published
2026-11-11
DOI
https://doi.org/10.3390/sclerosis4040033
Primary Topic
Systemic Sclerosis and Related Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Monocytes and Macrophages in Systemic Sclerosis: Profibrotic Functions and Emerging IRF8-Dependent Regulation

Yukie Yamaguchi
Sclerosis
Systemic Sclerosis and Related Diseases
article

Monocytes and Macrophages in Systemic Sclerosis: Profibrotic Functions and Emerging IRF8-Dependent Regulation

Yukie Yamaguchi
article en

Abstract

Systemic sclerosis (SSc) is a clinically distinct autoimmune connective tissue disease characterized by immune dysregulation, vasculopathy, and excessive fibrosis. Monocytes and macrophages (Mo/Mφ) contribute to these processes through heterogeneous tissue-dependent states that are not sufficiently represented by a binary M1/M2 framework. Human blood and tissue studies, including recent single-cell and spatial analyses, have repeatedly identified hybrid activated monocytes and monocyte-derived macrophages associated with skin or lung involvement. Classical studies have established several Mo/Mφ-linked profibrotic mechanisms in SSc, including the secretion of cytokines, chemokines, and growth factors; organization of macrophage–stromal signaling niches; production and remodeling of the extracellular matrix; monocyte plasticity toward vascular and mesenchymal lineages; and defective efferocytosis and resolution. Upstream of these effector outputs, transcriptional, epigenetic, and metabolic programs are increasingly recognized as key regulators. As one example relevant to Mo/Mφ differentiation, we have focused on interferon regulatory factor 8 (IRF8), showing reduced IRF8 expression in circulating monocytes from diffuse cutaneous SSc associated with skin fibrosis. Experimentally, IRF8 silencing and myeloid-specific Irf8 deletion promote profibrotic features; however, the functional direction of IRF8 across lineages and tissues remains incompletely defined. Several established and emerging SSc therapeutic strategies are thought to act at least in part on the Mo/Mφ compartment, although direct SSc-derived cellular evidence remains limited. This review synthesizes Mo/Mφ diversity and effector functions in SSc and outlines therapeutic implications, highlighting the need for lineage- and tissue-resolved profiling of Mo/Mφ and mechanistic dissection of their upstream programs as a foundation for rational therapeutic strategies in SSc.

SclerosisVol. 4(4)
Yokohama City University (JP)
Systemic Sclerosis and Related Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon